Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating subcutaneous abatacept with steroid treatment vs steroids alone in adults with Giant Cell Arteritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Orencia (abatacept) (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Giant Cell Arteritis | Phase 3 | Status: WITHDRAWN